IRIS
MUSOLINO, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.770
EU - Europa 2.101
AS - Asia 923
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 20
SA - Sud America 4
OC - Oceania 2
Totale 5.855
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.719
IE - Irlanda 832
CN - Cina 549
SE - Svezia 381
IT - Italia 321
SG - Singapore 289
DE - Germania 235
FI - Finlandia 98
UA - Ucraina 58
CA - Canada 51
AT - Austria 45
IN - India 44
CI - Costa d'Avorio 33
BE - Belgio 29
GB - Regno Unito 19
A1 - Anonimo 16
NL - Olanda 15
PL - Polonia 13
FR - Francia 12
TR - Turchia 12
CZ - Repubblica Ceca 9
ES - Italia 8
KR - Corea 7
RU - Federazione Russa 7
IR - Iran 6
EU - Europa 4
HR - Croazia 4
HK - Hong Kong 3
RO - Romania 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
CH - Svizzera 2
CL - Cile 2
IL - Israele 2
JP - Giappone 2
SC - Seychelles 2
TH - Thailandia 2
VN - Vietnam 2
AR - Argentina 1
AU - Australia 1
BR - Brasile 1
GR - Grecia 1
IS - Islanda 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.855
Salva come PNG Salva come JPEG
Città #
Dublin 817
Chandler 667
Ashburn 249
Beijing 238
Boardman 207
Singapore 197
Princeton 147
Ann Arbor 140
Shanghai 109
Bremen 105
Des Moines 80
New York 75
Helsinki 69
Jacksonville 59
Grafing 57
Seattle 57
Parma 56
Wilmington 55
Vienna 45
Montreal 35
Santa Clara 35
Abidjan 33
Dearborn 32
Milan 27
Nanjing 25
Brussels 22
San Mateo 22
Bologna 17
Shenyang 16
Woodbridge 15
Fairfield 14
Los Angeles 14
Rome 14
Jinan 13
Pune 13
Ardea 12
Rio Saliceto 12
Fremont 11
Borås 10
Izmir 9
Ravenna 9
Hebei 8
Nanchang 8
Rockville 8
Augusta 7
Falls Church 7
Madrid 7
Norwalk 7
Tianjin 7
Toronto 7
Changsha 6
Houston 6
Redwood City 6
Taiyuan 6
Ardabil 5
Dallas 5
Hefei 5
Kunming 5
Leawood 5
Munich 5
Pavia 5
Cascina 4
Guangzhou 4
Huizen 4
Olomouc 4
Reggio Emilia 4
Shenzhen 4
Stockholm 4
Washington 4
Zagreb 4
Zhengzhou 4
Andover 3
Atlanta 3
Brooklyn 3
Hangzhou 3
Jiaxing 3
Monmouth Junction 3
Rovereto 3
Suwon 3
Taipei 3
Trieste 3
Verona 3
Wenzhou 3
Amsterdam 2
Assago 2
Auburn Hills 2
Bangkok 2
Banja Luka 2
Bastia umbra 2
Brno 2
Capriate San Gervasio 2
Chicago 2
Collecchio 2
Daejeon 2
Dong Ket 2
Forlimpopoli 2
Frankfurt am Main 2
Haikou 2
Kocaeli 2
London 2
Totale 4.074
Salva come PNG Salva come JPEG
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 159
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 85
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 75
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 74
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 71
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 65
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 63
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 62
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 62
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 60
p73 and p53 pathway in human breast cancers. 60
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 58
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 57
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 57
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 57
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 57
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 56
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 56
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 56
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 55
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 55
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 54
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 54
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 53
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 53
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 53
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 52
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 52
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 52
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 51
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 51
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 50
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 50
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 49
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 49
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 49
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 49
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 49
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 48
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 48
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 48
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 48
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 47
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 47
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 47
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 46
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 46
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 46
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 46
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 45
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 45
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 45
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 44
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 43
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 43
A review of immune checkpoint blockade in breast cancer 43
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 42
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 42
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 42
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 42
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 42
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 41
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 41
Role of Fcγ receptors in HER2-targeted breast cancer therapy 41
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 40
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 40
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 39
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 39
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 39
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 39
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 39
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 39
A narrative review of the principal glucocorticoids employed in cancer 39
My best choice after a round trip from illness 37
FCGR, Cetuximab, and Colorectal Cancer Survival-Letter 36
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 36
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 36
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 35
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 35
TransCHERLob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer 35
Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFRexpressing metastatic colorectal cancer patients treated with cetuximab based therapy 35
Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial 35
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 35
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 34
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 34
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 33
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 32
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) 32
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 32
Survival prediction of terminally ill cancer patients by clinical parameter: usefulness role of simple prognostic indicator, as braden score 32
BRCA1 status, molecular markers, clinical variables in breast cancer patients with high probability of having an inherited genetic mutation 32
Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFRexpressing metastatic colorectal cancer patients treated with cetuximabbased therapy 32
DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC) 32
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy 31
Reply to Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large BCell NonHodgkin Lymphoma 31
In reply 30
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 30
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 29
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumabbased treatment in patients with HER2/ neupositive metastatic breast cancer 29
Osteooncologia 28
Totale 4.669
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020615 0 0 14 2 23 29 23 10 26 379 88 21
2020/2021389 17 44 11 13 31 25 43 35 68 12 70 20
2021/2022622 23 11 24 28 16 67 32 42 41 26 26 286
2022/20232.680 328 196 134 177 260 255 18 183 952 23 122 32
2023/20241.097 53 112 16 32 97 225 106 117 40 79 64 156
2024/2025512 70 209 233 0 0 0 0 0 0 0 0 0
Totale 6.104